Last reviewed · How we verify
IVIG infusion
IVIG (intravenous immunoglobulin) provides passive immunity by delivering pooled antibodies from multiple donors to modulate immune responses and neutralize pathogens or autoimmune mediators.
IVIG (intravenous immunoglobulin) provides passive immunity by delivering pooled antibodies from multiple donors to modulate immune responses and neutralize pathogens or autoimmune mediators. Used for Primary immunodeficiency disorders, Chronic inflammatory demyelinating polyneuropathy (CIDP), Multifocal motor neuropathy.
At a glance
| Generic name | IVIG infusion |
|---|---|
| Also known as | Intravenous Immunoglobulin, IgG |
| Sponsor | McMaster University |
| Drug class | Immunoglobulin replacement therapy / Immunomodulator |
| Target | Multiple (Fc receptors, complement system, pathogen-specific antigens) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Hematology |
| Phase | Phase 3 |
Mechanism of action
IVIG is a blood product containing immunoglobulin G (IgG) antibodies extracted and purified from the plasma of thousands of healthy donors. It works through multiple mechanisms including direct neutralization of pathogens and toxins, opsonization to enhance clearance, blockade of Fc receptors on immune cells to reduce inflammation, and provision of anti-idiotypic antibodies that suppress autoimmune responses. The exact therapeutic mechanism varies by indication but generally involves immune modulation and passive antibody replacement.
Approved indications
- Primary immunodeficiency disorders
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
- Multifocal motor neuropathy
- Immune thrombocytopenia (ITP)
- Kawasaki disease
Common side effects
- Headache
- Fever
- Chills
- Myalgia
- Infusion site reactions
- Aseptic meningitis
- Thromboembolism
- Acute kidney injury
Key clinical trials
- A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PHASE3)
- A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma (PHASE3)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PHASE3)
- A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy (PHASE3)
- Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study (PHASE4)
- Treatment of Antibody-Mediated Rejection (ABMR) With CarBel (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IVIG infusion CI brief — competitive landscape report
- IVIG infusion updates RSS · CI watch RSS
- McMaster University portfolio CI